Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adherent-invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial at the Icahn School of Medicine at the Mount Sinai Hospital in New York, NY and the Johns Hopkins University in the Baltimore, MD metro area. The trial, registered under clinicaltrials.gov NCT03808103, is currently recruiting volunteers with inactive Crohn's disease.
For questions on the phage study, please contact the study coordinators:
In New York: Amy.firstname.lastname@example.org.
In Maryland: email@example.com.
See one of the trial's clinical investigators and IBD expert, Dr. Robert Hirten, discuss this exciting new bacteriophage therapy trial at: https://www.facebook.com/mountsinainyc
Intralytix, Inc.'s VRELysin™ bacteriophage therapy targeting vancomycin resistant Enterococci colonization in the gastrointestinal tract has entered a Phase 1/2a clinical trial at the University of Pittsburgh Medical Center in Pittsburgh, PA. The trial, registered under clinicaltrials.gov NCT05715619, is currently recruiting healthy volunteers for Phase 1.
For questions on the phage study, please contact firstname.lastname@example.org